Papers - Sanuki, Naoko

Dose distribution analysis of axillary lymph nodes for three-dimensional conformal radiotherapy with a field-in-field technique for breast cancer.

 2009.01

• Access to Document (DOI)

Discrepancy between the intended isocenter and that from orthogonal linacgrams in the treatment of CT-guided stereotactic body radiotherapy(SBRT)

Oooka, Y. and Takeda, A. and Sudo, Y. and Iwashita, H. and Aoki, Y. and Katayose, T. and Sasajima, N. and Sanuki, N. and Oohashi, T. and Kunieda, E. and Nagaoka, T.

Nippon Hoshasen Gijutsu Gakkai zasshi 65 ( 1 ) 41 - 49 2009

ISSN  03694305

• Access to Document (DOI)

Future strategies in chemoradiotherapy for stage III non-small cell lung cancer

Ishikura, S. and Sanuki, N. and Ito, Y. and Nihei, K.

Japanese Journal of Clinical Radiology 54 ( 7 ) 851 - 856 2009

ISSN  00099252

Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing.

 2008.10

• Access to Document (DOI)

Pattern of tumor recurrence in initially nonmetastatic breast cancer patients

Cancer  2008.08

ISSN  0008-543X

　View Summary

<jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND.</jats:title><jats:p>Breast cancer is likely to have systemic involvement. However, to the authors' knowledge there are few reports to date regarding clinically detected patterns of metastasis, meticulously studied in regard to the natural history of breast cancer, including unusual sites of metastasis.</jats:p></jats:sec><jats:sec><jats:title>METHODS.</jats:title><jats:p>Patients treated for invasive breast cancer from April 1983 to May 2007 were retrospectively analyzed. Patterns of clinically apparent tumor recurrence, focusing especially on unusual metastases, were studied as well as possible risk factors for unusual metastases and their influence on survival.</jats:p></jats:sec><jats:sec><jats:title>RESULTS.</jats:title><jats:p>Overall, 3783 patients were eligible for the current analysis. The median duration of follow‐up was 5.0 years (range, 0.6 years–20.4 years). Cumulative 5‐year and 10‐year survival rates were 89.7% and 81.5%, respectively. “Unusual metastasis” was defined as systemic failure with a frequency of ≤1%; in the current series; it was observed in 85 (2.2%) patients %. Of those, 70 (82%) had preceding metastasis in the usual sites. The median duration until the development of usual and unusual metastasis was 2.3 years and 3.6 years, respectively (<jats:italic>P</jats:italic> &lt; .0001). Among764 patients with distant metastasis, the 5‐year cumulative overall survival rate in those with or without unusual metastasis was 53.5% and 53.4 years, respectively (<jats:italic>P</jats:italic> = .33). No risk factors for unusual metastasis were identified.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS.</jats:title><jats:p>This retrospective study examined the frequency of unusual metastases in a large number of Japanese patients with initially nonmetastatic breast cancer. The prognosis of patients with unusual metastases was found to be similar to that of patients with metastasis only at more usual sites. Cancer 2008. © 2008 American Cancer Society.</jats:p></jats:sec>

• Access to Document (DOI)

Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer.

 2008.03

• Access to Document (DOI)

Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity.

 2008.01

• Access to Document (DOI)

Radiation therapy after breast-conserving surgery.

 2006.06

• Access to Document (DOI)

Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer

Ito, Y. and Okusaka, T. and Kagami, Y. and Ueno, H. and Ikeda, M. and Sumi, M. and Imai, A. and Fujimoto, N. and Ikeda, H.

Anticancer Research 26 ( 5 B ) 3755 - 3759 2006

Pro‐gastrin–releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation

Cancer  2005.08

ISSN  0008-543X

　View Summary

<jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastasis with an effect on overall survival in patients with small cell lung carcinoma (SCLC). In spite of multidisciplinary intensive treatment approaches, many patients still experience brain metastasis. The authors retrospectively analyzed the characteristics of the first failure event due to brain metastasis (FBM) in patients treated with PCI.</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>Between January 1990 and April 2004, 71 patients with limited disease SCLC were treated with PCI after completing systemic treatment at the National Cancer Center Hospital (Tokyo, Japan). Univariate and multivariate analyses were used to identify factors related to FBM and survival.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>The FBM and overall incidence of brain metastasis (OBM) were 16.9 % (12 of 71) and 26.8% (19 of 71), respectively. Median time to progressive disease and median survival were 8.4 months and 21.6 months, respectively. Elevation of pro‐gastrin–releasing peptide (Pro GRP) level before PCI was found to be a significant predictive and prognostic factor for FBM, OBM, and survival on multivariate analysis (<jats:italic>P</jats:italic> = 0.007, <jats:italic>P</jats:italic> = 0.025, and <jats:italic>P</jats:italic> = 0.009, respectively).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>An elevated Pro GRP level before PCI was found to be significantly related to FBM and survival, and should be considered before PCI is performed. Cancer 2005. © 2005 American Cancer Society.</jats:p></jats:sec>

• Access to Document (DOI)

Benefits of axillary radiotherapy unclear in women with early stage breast cancer undergoing conservative breast surgery without axillary dissection

Sanuki-Fujimoto, N.

Cancer Treatment Reviews 31 ( 6 ) 496 - 500 2005

• Access to Document (DOI)

Treatment of breast carcinoma in patients with clinically negative axillary lymph nodes using radiotherapy versus axillary dissection

Fujimoto, N. and Amemiya, A. and Kondo, M. and Takeda, A. and Shigematsu, N.

Cancer 101 ( 10 ) 2155 - 2163 2004

• Access to Document (DOI)

A new bisphosphonate treatment option for giant cell tumors

Oncology Reports  2001.05

ISSN  1021-335X

• Access to Document (DOI)